Long-Term Results of Anti– Helicobacter pylori Therapy in Early-Stage Gastric High-Grade Transformed MALT Lymphoma
Open Access
- 21 September 2005
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 97 (18), 1345-1353
- https://doi.org/10.1093/jnci/dji277
Abstract
Background: Several independent clinical studies have reported that Helicobacter pylori eradication therapy could achieve complete remission in some patients with H. pylori –positive early-stage gastric mucosa–associated lymphoid tissue (MALT) lymphoma. Methods: To compare the long-term results of anti– H. pylori therapy in early-stage, gastric low-grade and high-grade transformed MALT lymphoma, two multicenter prospective studies of anti– H. pylori therapy for early-stage gastric lymphoma conducted in Taiwan, one for low-grade MALT lymphoma, with 34 patients enrolled from March 1996 through April 1999, and one for high-grade transformed tumors (diffuse large B-cell lymphoma with features of MALT, DLBCL[MALT] lymphoma), with 24 patients enrolled since June 1995, were directly compared. In both studies, patients generally received 2 weeks of antibiotics and had multiple sequential follow-up endoscopic examinations until complete histologic remission (CR) or disease progression; patients were monitored through January 31, 2004. CR was defined as regression of lymphoid infiltration to Wotherspoon's score of 2 or less on all pathologic sections of endoscopic biopsy specimens. All statistical tests were two-sided. Results: The H. pylori –positive rate among the 34 low-grade patients was 94% (32 of 34). All 24 selected high-grade patients were H. pylori positive. H. pylori was eradicated in 97% (30 of 31) of evaluable H. pylori –positive low-grade patients and in 92% (22 of 24) of high-grade patients, which led to CR in 80% (24 of 30, 95% confidence interval [CI] = 65% to 95%) and 64% (14 of 22, 95% CI = 42% to 86%) of patients, respectively. None of the five patients who were either initially H. pylori negative or had persistent H. pylori infection after antibiotics achieved CR. After median follow-up of more than 5 years in complete responders, tumor recurrence was observed in three (13%) low-grade patients but not in high-grade patients. Conclusions: Anti– H. pylori therapy may be considered as one of the treatment options for early-stage H. pylori –positive gastric DLBCL(MALT), and large-scale prospective studies to validate its use as first-line therapy for such tumors should be undertaken.This publication has 38 references indexed in Scilit:
- Gastric low-grade B-cell MALT lymphoma: treatment, response, and genetic alterationThe Esophagus, 2003
- Regression of gastric high grade mucosa associated lymphoid tissue (MALT) lymphoma after Helicobacter pylori eradicationGut, 2001
- Regression of High-Grade Gastric B-Cell Lymphoma After Eradication of Helicobacter PyloriEndoscopy, 2001
- Bcl10 and MALT1, Independent Targets of Chromosomal Translocation in MALT Lymphoma, Cooperate in a Novel NF-κB Signaling PathwayPublished by Elsevier BV ,2001
- Predictive value of endoscopic ultrasonography for regression of gastric low grade and high grade MALT lymphomas after eradication of Helicobacter pyloriGut, 2001
- Predictive factors for regression of gastric MALT lymphoma after anti-Helicobacter pylori treatmentGut, 2001
- The Product of the t(11;18), an API2-MLT Fusion, Marks Nearly Half of Gastric MALT Type Lymphomas without Large Cell ProliferationThe American Journal of Pathology, 2000
- Exclusive Detection of the t(11;18)(q21;q21) in Extranodal Marginal Zone B Cell Lymphomas (MZBL) of MALT Type in Contrast to other MZBL and Extranodal Large B Cell LymphomasThe American Journal of Pathology, 1999
- Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pyloriThe Lancet, 1993
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958